Vaxcyte Inc - Asset Resilience Ratio
Vaxcyte Inc (PCVX) has an Asset Resilience Ratio of 45.54% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read PCVX current and long-term liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2020–2025)
This chart shows how Vaxcyte Inc's Asset Resilience Ratio has changed over time. See what is Vaxcyte Inc's book value for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Vaxcyte Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Vaxcyte Inc market cap and net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $1.39 Billion | 45.54% |
| Total Liquid Assets | $1.39 Billion | 45.54% |
Asset Resilience Insights
- Very High Liquidity: Vaxcyte Inc maintains exceptional liquid asset reserves at 45.54% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Vaxcyte Inc Industry Peers by Asset Resilience Ratio
Compare Vaxcyte Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
GlycoMimetics Inc
NASDAQ:GLYC |
Biotechnology | 91585.83% |
|
Argen-X
F:1AE |
Biotechnology | 25.67% |
|
Samsung Biologics Co Ltd
KO:207940 |
Biotechnology | 5.66% |
|
Royalty Pharma Plc
NASDAQ:RPRX |
Biotechnology | 0.10% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 3.28% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Abivax SA American Depositary Shares
NASDAQ:ABVX |
Biotechnology | 2.34% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
Annual Asset Resilience Ratio for Vaxcyte Inc (2020–2025)
The table below shows the annual Asset Resilience Ratio data for Vaxcyte Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 45.54% | $1.39 Billion | $3.05 Billion | +6.82pp |
| 2024-12-31 | 38.71% | $1.36 Billion | $3.51 Billion | -9.78pp |
| 2023-12-31 | 48.50% | $682.78 Million | $1.41 Billion | +38.88pp |
| 2022-12-31 | 9.61% | $96.72 Million | $1.01 Billion | -44.96pp |
| 2021-12-31 | 54.57% | $176.99 Million | $324.34 Million | -- |
| 2020-12-31 | 0.00% | $0.00 | $392.83 Million | -- |
About Vaxcyte Inc
Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants. The company also develops VAX-31, a 31-valent, carrie… Read more